SCA
PACB icon

SAC Capital Advisors’s Pacific Biosciences PACB Stock Holding History

SAC Capital Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10,300
Closed -$55K – 732
2014
Q1 		$55K Buy
+10,300
New +$65.1K ﹤0.01% 1704

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAC Capital Advisors's PACB Position: Q2 2014 in Review

SAC Capital Advisors sold out of Pacific Biosciences (PACB) in Q2 2014, closing a stake of 10,300 shares — an estimated $55K sold.

SAC Capital Advisors first reported a position in PACB in Q1 2014 and held it in 1 quarter. The position peaked at $55K in Q1 2014. 86 funds tracked by Wall St. Rank hold PACB as of Q2 2014.

  • SAC Capital Advisors reported no remaining Pacific Biosciences position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 10,300 Pacific Biosciences shares in Q2 2014, an estimated $55K.
  • SAC Capital Advisors first reported a position in Pacific Biosciences in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Pacific Biosciences position peaked at $55K in Q1 2014.
  • 86 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.